186 related articles for article (PubMed ID: 29861875)
1. The B cell receptor signaling pathway in mantle cell lymphoma.
Merolle MI; Ahmed M; Nomie K; Wang ML
Oncotarget; 2018 May; 9(38):25332-25341. PubMed ID: 29861875
[TBL] [Abstract][Full Text] [Related]
2. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
3. Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Seiler T; Dreyling M
Expert Opin Investig Drugs; 2017 Aug; 26(8):909-915. PubMed ID: 28661188
[TBL] [Abstract][Full Text] [Related]
4. Protein Kinase CK1α Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma.
Manni S; Fregnani A; Quotti Tubi L; Spinello Z; Carraro M; Scapinello G; Visentin A; Barilà G; Pizzi M; Dei Tos AP; Vianello F; Zambello R; Gurrieri C; Semenzato G; Trentin L; Piazza F
Front Oncol; 2021; 11():733848. PubMed ID: 34722279
[TBL] [Abstract][Full Text] [Related]
5. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
[TBL] [Abstract][Full Text] [Related]
6. Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.
Profitós-Pelejà N; Santos JC; Marín-Niebla A; Roué G; Ribeiro ML
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205606
[TBL] [Abstract][Full Text] [Related]
7. Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.
Akhter A; Street L; Ghosh S; Burns BF; Elyamany G; Shabani-Rad MT; Stewart DA; Mansoor A
Hematol Oncol; 2017 Mar; 35(1):79-86. PubMed ID: 26354285
[TBL] [Abstract][Full Text] [Related]
8. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.
Ondrisova L; Mraz M
Front Oncol; 2020 Oct; 10():591577. PubMed ID: 33154951
[TBL] [Abstract][Full Text] [Related]
9. HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton's Tyrosine Kinase Inhibitor Ibrutinib.
Lu Z; Wang Z; Tu Z; Liu H
Front Pharmacol; 2022; 13():864194. PubMed ID: 35721157
[TBL] [Abstract][Full Text] [Related]
10. Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.
Xia B; Qu F; Yuan T; Zhang Y
Oncol Lett; 2015 Dec; 10(6):3339-3344. PubMed ID: 26788133
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
Karvonen H; Chiron D; Niininen W; Ek S; Jerkeman M; Moradi E; Nykter M; Heckman CA; Kallioniemi O; Murumägi A; Ungureanu D
Blood Adv; 2017 Nov; 1(24):2257-2268. PubMed ID: 29296874
[TBL] [Abstract][Full Text] [Related]
13. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
Robak T; Robak P
Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.
Stephens DM; Spurgeon SE
Ther Adv Hematol; 2015 Oct; 6(5):242-52. PubMed ID: 26425337
[TBL] [Abstract][Full Text] [Related]
15. B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Koehrer S; Burger JA
Clin Adv Hematol Oncol; 2016 Jan; 14(1):55-65. PubMed ID: 27057669
[TBL] [Abstract][Full Text] [Related]
16. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma.
Balsas P; Esteve-Arenys A; Roldán J; Jiménez L; Rodríguez V; Valero JG; Chamorro-Jorganes A; de la Bellacasa RP; Teixidó J; Matas-Céspedes A; Moros A; Martínez A; Campo E; Sáez-Borderías A; Borrell JI; Pérez-Galán P; Colomer D; Roué G
J Hematol Oncol; 2017 Mar; 10(1):80. PubMed ID: 28359287
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib in B-cell lymphoma: single fighter might be enough?
Xue C; Wang X; Zhang L; Qu Q; Zhang Q; Jiang Y
Cancer Cell Int; 2020; 20():467. PubMed ID: 33005100
[TBL] [Abstract][Full Text] [Related]
18. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
19. Protein Kinase CK2 represents a new target to boost Ibrutinib and Venetoclax induced cytotoxicity in mantle cell lymphoma.
Manni S; Pesavento M; Spinello Z; Saggin L; Arjomand A; Fregnani A; Quotti Tubi L; Scapinello G; Gurrieri C; Semenzato G; Trentin L; Piazza F
Front Cell Dev Biol; 2022; 10():935023. PubMed ID: 36035991
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma.
Vann KR; Pal D; Smith AL; Sahar NE; Krishnaiah M; El-Gamal D; Kutateladze TG
Mol Biomed; 2022 Jan; 3(1):2. PubMed ID: 35031886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
